Literature DB >> 1378455

Antibody responses to lipid A, core, and O sugars of the Pseudomonas aeruginosa lipopolysaccharide in chronically infected cystic fibrosis patients.

G Kronborg1, A Fomsgaard, C Galanos, M A Freudenberg, N Høiby.   

Abstract

Enzyme-linked immunosorbent assays were developed separately for the three main parts of the Pseudomonas aeruginosa lipopolysaccharide (LPS) molecule, namely, lipid A, core, and O polysaccharide. Anti-lipid A, anticore, and anti-O polysaccharide antibodies were measured in serum samples from 12 patients with cystic fibrosis (CF) in a longitudinal study covering the period before P. aeruginosa infection was established through at least 5 years of chronic infection. The serum antibody response to all parts of the P. aeruginosa LPS molecule increased during the course of chronic infection. The increase in anti-lipid A antibodies was specific for P. aeruginosa lipid A, since no increase in anti-Escherichia coli lipid A antibodies was seen. Immunoglobulin G, A, and M (IgG, IgA and IgM) antibodies were all involved in the specific systemic response to P. aeruginosa lipid A, core, and the O polysaccharides. IgG and IgA levels in particular increased during the course of infection and were significantly higher than the antibody increase seen with age in a healthy control group. The local immune response in the lungs was investigated by measuring IgG, IgA, and IgM antibodies to the separate parts of the P. aeruginosa LPS molecule in sputum samples from 18 CF patients with at least a 5-year history of chronic P. aeruginosa infection. Antibodies detected in sputum were mainly anti-lipid A and anti-O polysaccharide antibodies of the IgG and IgA isotypes. Very high IgA anti-lipid A titers were detected in sputum samples from some CF patients.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1378455      PMCID: PMC265392          DOI: 10.1128/jcm.30.7.1848-1855.1992

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  34 in total

1.  Prevalence and persistence of polyagglutinable Pseudomonas aeruginosa in isolates from cystic fibrosis patients.

Authors:  B Ojeniyi; N Høiby; V T Rosdahl
Journal:  APMIS       Date:  1991-02       Impact factor: 3.205

2.  The metabolic fate of endotoxins.

Authors:  M A Freudenberg; C Galanos
Journal:  Prog Clin Biol Res       Date:  1988

3.  A new method for the extraction of R lipopolysaccharides.

Authors:  C Galanos; O Lüderitz; O Westphal
Journal:  Eur J Biochem       Date:  1969-06

4.  Lipopolysaccharide is present in immune complexes isolated from sputum in patients with cystic fibrosis and chronic Pseudomonas aeruginosa lung infection.

Authors:  G Kronborg; G H Shand; A Fomsgaard; N Høiby
Journal:  APMIS       Date:  1992-02       Impact factor: 3.205

5.  Bacteraemia and fungaemia in adults with cystic fibrosis.

Authors:  J V Fahy; M T Keoghan; E J Crummy; M X FitzGerald
Journal:  J Infect       Date:  1991-05       Impact factor: 6.072

6.  Pseudomonas aeruginosa isolates from patients with cystic fibrosis: a class of serum-sensitive, nontypable strains deficient in lipopolysaccharide O side chains.

Authors:  R E Hancock; L M Mutharia; L Chan; R P Darveau; D P Speert; G B Pier
Journal:  Infect Immun       Date:  1983-10       Impact factor: 3.441

7.  Comparative immunochemistry of lipopolysaccharides from typable and polyagglutinable Pseudomonas aeruginosa strains isolated from patients with cystic fibrosis.

Authors:  A Fomsgaard; R S Conrad; C Galanos; G H Shand; N Høiby
Journal:  J Clin Microbiol       Date:  1988-05       Impact factor: 5.948

8.  Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group.

Authors:  E J Ziegler; C J Fisher; C L Sprung; R C Straube; J C Sadoff; G E Foulke; C H Wortel; M P Fink; R P Dellinger; N N Teng
Journal:  N Engl J Med       Date:  1991-02-14       Impact factor: 91.245

9.  Role of lipopolysaccharide in opsonization and phagocytosis of Pseudomonas aeruginosa.

Authors:  W Engels; J Endert; M A Kamps; C P van Boven
Journal:  Infect Immun       Date:  1985-07       Impact factor: 3.441

10.  Correlation of the biologic responses of C3H/HEJ mice to endotoxin with the chemical and structural properties of the lipopolysaccharides from Pseudomonas aeruginosa and Escherichia coli.

Authors:  G B Pier; R B Markham; D Eardley
Journal:  J Immunol       Date:  1981-07       Impact factor: 5.422

View more
  14 in total

1.  Dewetting-induced formation and mechanical properties of synthetic bacterial outer membrane models (GUVs) with controlled inner-leaflet lipid composition.

Authors:  Sepehr Maktabi; Jeffrey W Schertzer; Paul R Chiarot
Journal:  Soft Matter       Date:  2019-05-15       Impact factor: 3.679

2.  Immunization with Pseudomonas aeruginosa vaccines and adjuvant can modulate the type of inflammatory response subsequent to infection.

Authors:  H K Johansen; F Espersen; S J Cryz; H P Hougen; A Fomsgaard; J Rygaard; N Høiby
Journal:  Infect Immun       Date:  1994-08       Impact factor: 3.441

3.  Specific IgG2 antibodies to Pseudomonas aeruginosa lipid A and lipopolysaccharide are early markers of chronic infection in patients with cystic fibrosis.

Authors:  G Kronborg; T Pressler; A Fomsgaard; C Koch; N Høiby
Journal:  Infection       Date:  1993 Sep-Oct       Impact factor: 3.553

4.  Quorum sensing and virulence of Pseudomonas aeruginosa during lung infection of cystic fibrosis patients.

Authors:  Thomas Bjarnsholt; Peter Østrup Jensen; Tim Holm Jakobsen; Richard Phipps; Anne Kirstine Nielsen; Morten Theil Rybtke; Tim Tolker-Nielsen; Michael Givskov; Niels Høiby; Oana Ciofu
Journal:  PLoS One       Date:  2010-04-12       Impact factor: 3.240

5.  Sera from adult patients with cystic fibrosis contain antibodies to Pseudomonas aeruginosa type III apparatus.

Authors:  J Moss; M E Ehrmantraut; B D Banwart; D W Frank; J T Barbieri
Journal:  Infect Immun       Date:  2001-02       Impact factor: 3.441

6.  Lipopolysaccharide exposure is linked to activation of the acute phase response and growth failure in pediatric Crohn's disease and murine colitis.

Authors:  Brad A Pasternak; Sharon D'Mello; Ingrid I Jurickova; Xiaonan Han; Tara Willson; Leah Flick; Lisa Petiniot; Naonori Uozumi; Senad Divanovic; Anna Traurnicht; Erin Bonkowski; Subra Kugathasan; Christopher L Karp; Lee A Denson
Journal:  Inflamm Bowel Dis       Date:  2010-05       Impact factor: 5.325

7.  Enhancement of lipopolysaccharide-induced tumor necrosis factor secretion by hyperimmune serum from chronic infected patients.

Authors:  G Kronborg; A Fomsgaard; N Høiby
Journal:  Med Microbiol Immunol       Date:  1993-12       Impact factor: 3.402

8.  Antibodies against chromosomal beta-lactamase.

Authors:  B Giwercman; J W Rasmussen; O Cioufu; I Clemmentsen; H Schumacher; N Høiby
Journal:  Antimicrob Agents Chemother       Date:  1994-10       Impact factor: 5.191

9.  Increased nitric oxide excretion in patients with severe acute pancreatitis: evidence of an endotoxin mediated inflammatory response?

Authors:  S H Rahman; B J Ammori; M Larvin; M J McMahon
Journal:  Gut       Date:  2003-02       Impact factor: 23.059

10.  Proteomic identification of OprL as a seromarker for initial diagnosis of Pseudomonas aeruginosa infection of patients with cystic fibrosis.

Authors:  Aparna R Rao; Anita Laxova; Philip M Farrell; Joseph T Barbieri
Journal:  J Clin Microbiol       Date:  2009-06-24       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.